Stanford Cancer Institute Directory
Lymphoma & Leukemia Profiles
Showing 21 - 25 of 25
Shelagh Galligan Professor in the School of Medicine
Dr. Sakamoto received her B.A. in Biology from Williams College and her M.D. from the University of Cincinnati. She was a pediatric resident and hematology/oncology fellow at Children’s Hospital Los Angeles. Dr. Sakamoto was a research fellow at UCLA and then was a faculty member at UCLA in the Department of Pediatrics, Division of Hematology/Oncology for over 20 years. She received her Ph.D. in Biology from the California Institute of Technology. Dr. Sakamoto was the Division Chief of Pediatric Hematology/Oncology at UCLA for six years and was the Vice-Chair of Research in the Department of Pediatrics; co-Associate Director of the Signal Transduction Program Area of the UCLA Jonsson Comprehensive Cancer Center, and co-Chair of the UCLA Clinical and Translational Science Institute, Committee for Maternal, Child, and Adolescent Health. From 2011-2014, she was the Division Chief of Pediatric Hematology/Oncology/Stem Cell Transplant/Cancer Biology at Lucile Packard Children’s Hospital at Stanford. Dr. Sakamoto was the Fellowship Program Director and is the P.I. of an NIH T32 training grant at Stanford. Currently, she is a member of the Child Health Research Institute Executive Committee at Stanford University and the Academic Promotion Committee for Stanford School of Medicine. Dr. Sakamoto’s research has focused on signaling pathways and gene regulation in normal and aberrant hematopoiesis, including leukemia and bone marrow failure syndromes. She is specifically interested in targeted therapies for leukemia and other types of pediatric cancers. Dr. Sakamoto has been funded by the National Institutes of Health for over 20 years. She currently holds the Shelagh Galligan Endowed Professorship and has received awards from the American Cancer Society, Leukemia & Lymphoma Society, Bear Necessities, and CDMRP(DOD). She has been a standing and ad hoc member of National Institutes of Health grant review committees for the past 15 years. She is Chair of the Bear Necessities Scientific Review Committee. She is currently developing novel therapies to target CREB for the treatment of acute leukemia. Promising small molecule compounds that are effective in the lab and nontoxic will be tested and optimized to take to the clinic for patients with relapsed leukemia. This will provide novel approaches to treat leukemia in children.
James H. Clark Professor in the School of Engineering and Professor of Chemical Engineering and of Bioengineering
Using and Understanding Cell-Free Biology Swartz Lab General Research Focus: The current and projected research in the Swartz lab balances basic research in microbial metabolism, protein expression, and protein folding with a strong emphasis on compelling applications. The power and versatility of cell-free methods coupled with careful evaluation and engineering of these new systems enables a whole new range of applications and scientific investigation. Fundamental research on: the mechanisms and kinetics of ribosomal function, fundamental bioenergetics, basic mechanisms of protein folding, functional genomics, and metabolic pathway analysis is motivated by a variety of near- and medium term applications spanning medicine, energy, and environmental needs. Swartz Lab Application Focus: In the medical area , current research addresses the need for patient-specific vaccines to treat cancer. Particularly for lymphomas, there is a strong need to be able to make a new cancer vaccine for each patient. Current technologies are not practical for this demanding task, but cell-free approaches are rapid and inexpensive. We have already demonstrated feasibility in mouse tumor challenge studies and are now expanding the range of applications and working to improve the relevant technologies. Experience with these vaccines has also suggested a new and exciting format for making inexpensive and very potent vaccines for general use. To address pressing needs for a new and cleaner energy source, we are working towards an organism that can efficiently capture solar energy and convert it into hydrogen. The first task is to develop an oxygen tolerant hydrogenase using cell-free technology to express libraries of mutated enzymes that can be rapidly screened for improved function. Even though these are very complex enzymes, we have produced active hydrogenases with our cell-free methods. We are now perfecting the screening methods for rapid and accurate identification of improved enzymes. After these new enzymes are identified, the project will progress toward metabolic engineering and bioreactor design research to achieve the scales and economies required. To address environmental needs, we are developing an improved water filters using an amazing membrane protein, Aquaporin Z. It has the ability to reject all other chemicals and ions except water. We have efficiently expressed the protein into lipid bilayer vesicles and are now working to cast these membranes on porous supports to complete the development of a new and powerful water purification technology. The same lessons will be applied toward the development of a new class of biosensors that brings high sensitivity and selectivity.
Professor of Biomedical Data Science and of Statistics
Robert Tibshirani's main interests are in applied statistics, biostatistics, and data mining. He is co-author of the books "Generalized Additive Models" (with Trevor Hastie, Stanford), "An Introduction to the Bootstrap" (with Brad Efron, Stanford), and "Elements of Statistical Learning" (with Trevor Hastie and Jerry Friedman, Stanford). His current research focuses on problems in biology and genomics, medicine, and industry. With Stanford collaborator Balasubramanian Narasimhan, he also develops software packages for genomics and proteomics.